CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Recognize the warning signs of a bad investment to protect your finances. Stay informed and make sound investment decisions.
18,560 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Emerging markets are outpacing the S&P 500 in 2026, with EEM posting a double-digit lead year-to-date. The rally cent...
Stitch Fix surprised investors with stronger-than-expected results, sparking a notable market move. This article brea...
With his 80th birthday approaching, Trump orchestrates high-profile appearances and a major White House event to proj...
Bitcoin cools after oil-driven volatility fades, shifting focus to liquidity, rate bets, and ETF flows as Brent trade...
Netflix has cooled off, and rumors about Warner Bros. and Roku fueled debate. This guide analyzes whether the pullbac...
Semiconductors led by the SMH and SOXX pulled back sharply, triggering fresh talk of a buyable dip. Famous tech inves...
ServiceNow sprinted higher on Friday as AI and automation headlines fueled optimism. This piece breaks down the catal...
Investors face a clear choice between two CRM juggernauts. This guide breaks down HubSpot and Salesforce, weighing gr...
As markets swing, a trio of unloved names—general mills, mattel, and mohawk—are drawing renewed attention from retire...
In 2026, investors face a choice between a pure digital disruptor in LatAm and a large US consumer lender with a heav...
Tesla faces a pivotal three-year outlook as margins recover and AI initiatives expand. Analysts sketch a base case ar...